Apr
05
This clinical trial aims to validate the results observed in I-SPY2 and will test if adding durvalumab to neoadjuvant chemotherapy can increase pCR rates, shift residual cancer burden to lower values and improve invasive breast cancer free survival in early-stage HRpositive MP2 cancers.
Cancer Genetics Program
Cancer Treatments
Ratna Vadlamudi, PhD, a professor of obstetrics and gynecology at the Mays Cancer Center, is researching compounds that can target cancer cells to stop their growth.